Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Astrid E. Slagter, Netherlands Cancer Institute
  • ,
  • Irene A. Caspers, Netherlands Cancer Institute, Amsterdam UMC
  • ,
  • Nicole C.T. van Grieken, Amsterdam UMC
  • ,
  • Iris Walraven, Netherlands Cancer Institute, Radboud University Nijmegen
  • ,
  • Pehr Lind, Karolinska Institutet
  • ,
  • Elma Meershoek Klein Kranenbarg, Leiden University
  • ,
  • Cecile Grootscholten, Netherlands Cancer Institute
  • ,
  • Marianne Nordsmark
  • Johanna W. van Sandick, Netherlands Cancer Institute
  • ,
  • Karolina Sikorska, Netherlands Cancer Institute
  • ,
  • Cornelis J.H. van de Velde, Leiden University
  • ,
  • Edwin P.M. Jansen, Netherlands Cancer Institute
  • ,
  • Marcel Verheij, Netherlands Cancer Institute, Radboud University Nijmegen
  • ,
  • Hanneke W.M. van Laarhoven, Amsterdam UMC
  • ,
  • Annemieke Cats, Netherlands Cancer Institute

(1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the curative setting as well. However, evidence to prefer oxaliplatin over cisplatin in the curative setting is limited. (2) Methods: We compared patientrelated and tumor-related outcomes for cisplatin versus oxaliplatin in patients with resectable gastric cancer treated with perioperative chemotherapy in the CRITICS trial. (3) Results: Preoperatively, 632 patients received cisplatin and 149 patients received oxaliplatin. Preoperative severe toxicity was encountered in 422 (67%) patients who received cisplatin versus 89 (60%) patients who received oxaliplatin (p = 0.105). Severe neuropathy was observed in 5 (1%) versus 6 (4%; p = 0.009) patients, respectively. Postoperative severe toxicity occurred in 109 (60%) versus 26 (51%) (p = 0.266) patients; severe neuropathy in 2 (1%) versus 2 (4%; p = 0.209) for patients who received cisplatin or oxaliplatin, respectively. Diarrhea impacted the quality of life more frequently in patients who received oxaliplatin compared to cisplatin. Complete or near-complete pathological response was achieved in 94 (21%) versus 16 (15%; p = 0.126) patients who received cisplatin or oxaliplatin, respectively. Overall survival was not significantly different in both groups (p = 0.300). (4) Conclusions: Both cisplatin and oxaliplatin are legitimate options as part of systemic treatment in patients with resectable gastric cancer.

OriginalsprogEngelsk
Artikelnummer2963
TidsskriftCancers
Vol/bind14
Nummer12
Antal sider17
ISSN2072-6694
DOI
StatusUdgivet - jun. 2022

Se relationer på Aarhus Universitet Citationsformater

ID: 281997750